Sex-differences in cancer occurrence and mortality are evident across tumor types; men exhibit higher 11 rates of incidence and often poorer responses to treatment. Targeted approaches to the treatment of tumors 12 that account for these sex-differences require the characterization and understanding of the fundamental 13 biological mechanisms that differentiate them. Hepatocellular Carcinoma (HCC) is the second leading 14 cause of cancer death worldwide, with the incidence rapidly rising. HCC exhibits a male-bias in 15 occurrence and mortality, but previous studies have failed to explore the sex-specific dysregulation of 16 gene expression in HCC. Here, we characterize the sex-shared and sex-specific regulatory changes in 17 HCC tumors in the TCGA LIHC cohort. By using sex-specific differential expression analysis of tumor 18 and tumor-adjacent samples, we uncovered etiologically relevant genes and pathways differentiating male 19 and female HCC. While both sexes exhibited activation of pathways related to apoptosis and p53 20 signaling, pathways involved in innate and adaptive immunity showed differential activation between the 21 sexes. Using eQTL analyses, we discovered germline variants with differential effects on tumor gene 22 expression between the sexes. 24.3% of the discovered eQTLs exhibit differential effects between the 23 sexes, illustrating the substantial role of sex in modifying the effects of eQTLs in HCC. The genes that 24 showed sex-specific dysregulation in tumors and those that harbored a sex-specific eQTL converge in 25 clinically relevant pathways, suggesting that the molecular etiologies of male and female HCC are 26 partially driven by differential genetic effects on gene expression. Overall, our results provide new insight 27 into the role of inherited genetic regulation of transcription in modulating sex-differences in HCC 28 etiology and provide a framework for future studies on sex-biased cancers.
138
(FC) threshold of 2 were used to select significant DEGs.
139
To reliably detect genes that are expressed in a sex-biased way in HCC but not in non-diseased liver or in 140 tumor-adjacent tissue, we examined genes that were DE in the male vs. female tumor comparison using 141 the previously described significance thresholds, but not in the male vs. female comparisons of normal or 142 tumor-adjacent samples with a relaxed significance threshold of FDR-adjusted p-value ≤ 0.1 and absolute 143 log2(FC) ≥ 0.
144
To detect genes that are dysregulated in tumors compared to matched tumor-adjacent samples in each sex, 145 we identified DEGs in the tumor vs. tumor-adjacent comparison of males, females, and in the whole 146 sample. DEGs that were identified in one sex but not in the other or in the combined analysis of both 147 sexes were considered sex-specific. DEGs identified in the combined analysis were considered sex-148 shared. This approach allows the identification of high-confidence sex-specific events that are a result of 149 the underlying biological differences as opposed to sampling or statistical power. ANOVA and Kruskal-
150
Wallis tests were used to test for equality of fold changes of sex-shared and sex-specific DEGs across 151 male, female, and all samples.
152

Overrepresentation of biological functions and canonical pathways 153
We further analyzed the sex-shared and sex-specific tumor vs. tumor-adjacent DEGs as well as the sex-154 specific eQTL target genes (eGenes) to identify sex-shared and sex-specific pathways driving HCC 155 etiology. We used the NetworkAnalyst webtool [27] , which utilizes a hypergeometric test to compute p-156 values for the overrepresentation of genes in regards to GO terms and KEGG and Reactome pathways.
7
Gene expression values are affected by genetic, environmental, and technical factors, many of which may 161 be unknown or unmeasured. Technical confounding factors introduce sources of variance that may greatly 162 reduce the statistical power of association studies, and even cause false signals [28] . Thus, it is necessary 163 to account for known and unknown technical confounders. This is often achieved by detecting a set of 164 latent confounding factors with methods such as principal component analysis (PCA) or Probabilistic
165
Estimation of Expression Residuals (PEER) [29] . These surrogate variables are then used as covariates in 166 downstream analyses. We derived 10 PEER factors from the filtered tumor gene expression data, and 167 used the weights of these factors as covariates in the eQTL analysis. We used the R package SNPRelate
168
[30] to perform PCA on the germline genotype data. We accounted for population structure by applying 169 the first three genotype PCs as covariates in the eQTL analysis.
eQTL analysis 171
We used eQTL analyses to detect germline genetic effects on tumor gene expression. Similar to the DE 172 analysis, we utilized combined and sex-stratified analyses to detect sex-shared and sex-specific effects.
173
Germline genotypes and tumor gene expression data from 248 male and 119 female donors in the TCGA
174
LIHC cohort were used in the eQTL analysis. Filtered count data was normalized by fitting the FPKM 175 values of each gene and sample to the quantiles of the normal distribution. To account for technical 176 confounders and population structure, 10 de novo PEER factors and three genotype principal components 177 were used as covariates. Cis-acting (proximal) eQTLs were detected by linear regression as implemented 178 in QTLtools v.1.1 [31] . Variants within 1Mb of the gene under investigation were considered for testing.
179
We used the permutation pass with 10,000 permutations to get adjusted p-values for associations between 180 the gene expression levels and the top-variants in cis: first, permutations are used to derive a nominal p-181 value threshold per gene that reflects the number of independent tests per cis-window. Then, QTLtools 182 uses a forward-backward stepwise regression to determine the best candidate variant per signal [31] .
183
FDR-adjusted p-values were calculated to correct for multiple phenotypes tested, and an adjusted p-value 184 threshold of 0.01 was used to select significant associations. To allow the comparison of effect sizes of 185 sex-specific and sex-shared eQTLs across the sexes, effects of each variant located within the 1Mb cis-186 window were obtained using the QTLtools nominal pass.
187
Similarly to the tumor vs. tumor-adjacent DEGs, eQTLs that were detected in one sex but not in the other 188 or in the combined analysis were considered sex-specific, while eQTLs detected in the combined analysis 189 were considered sex-shared. ANOVA and Kruskal-Wallis tests were used to test for equality of effect 190 sizes of sex-shared and sex-specific eQTLs across male, female, and all samples.
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Estimating statistical power in the eQTL analysis 192
We used the R package powereQTL [32] to estimate the effect of the sample size to the statistical power 193 to detect eQTLs in the combined analysis of both sexes and in the sex-specific analyses ( Fig. S2 ).
194
Genomic annotations of eQTLs 195
We used the R package Annotatr to annotate the genomic locations of eQTLs [33] . Variant sites were 196 annotated for promoters, 5'UTRs, exons, introns, 3'UTRs, CpGs (CpG islands, CpG shores, CpG shelves),
197
and putative regulatory regions based on ChromHMM [34] annotations.
198
Results
199
Sex-specific patterns of gene expression in HCC 200
We identified sex-differences in gene expression in non-diseased liver (GTEx; 21 sex-biased genes with 201 an FDR-adjusted p-value ≤ 0.01 and an absolute log2FC ≥ 2), tumor-adjacent tissue (TCGA LIHC; 21 202 genes), and HCC (TCGA LIHC; 53 genes) to characterize the shared and unique sex-differences that may 203 drive the observed sex-biases in HCC occurrence and etiology ( Fig. 1 , Supplementary Tables S3-5 ). X-204 linked XIST and Y-linked genes were expressed in a sex-biased way across all tissues. While sex-biased 205 gene expression in non-diseased and tumor-adjacent tissues may contribute to the sex-differences in 206 cancer occurrence, sex-biased expression in tumors is suggestive of distinct molecular etiologies of male 207 and female HCC. We identified 34 genes that show sex-differences in expression in HCC, but not in 208 tumor-adjacent tissue or non-diseased liver, even with a relaxed significance threshold ( Fig. 1A) . Notably,
209
Notch-regulating DTX1 (Fig. 1B ) and signal transducer CD24 were downregulated in male HCC.
210
To further examine the sex-shared and sex-specific mechanisms driving HCC etiology, we detected DEGs 211 between tumor and tumor-adjacent samples in males and females, as well as in the combined analysis of 212 both sexes. Dimensionality reduction of gene expression data shows that variation among the tumor and 213 tumor-adjacent samples is driven by tissue type and sex (Fig. 1C) . When inspecting the tumor samples 214 only, the first dimension is largely driven by sex ( Supplementary Fig. S1 ). In the combined analysis of 215 male and female samples, we detected 691 tumor vs. tumor-adjacent DEGs ( Supplementary Table S6 ). In 216 male-and female-specific analyses, we detected 715 and 542 tumor vs. tumor-adjacent DEGs, 217 respectively ( Supplementary Tables S7 and S8 ). Out of the total of 903 unique DEGs, 76.5% were shared 218 between the sexes. We identified 103 female-specific and 108 male-specific tumor vs. tumor-adjacent 219 DEGs. Notably, substantially more DEGs were detected in sex-specific analyses than in the unstratified 220 9 analysis ( Fig. 1D ). Specifically, DEGs that showed different magnitudes in fold change between the sexes 221 (based on ANOVA/Kruskal-Wallis tests) were detected in the sex-specific analyses (Fig. 2C, 2D ), while 222 DEGs with similar fold changes across all comparisons were detected in the combined analysis as well as 223 the sex-specific analyses ( Fig. 2A ). Sex-shared DEGs that were only detected in the combined analysis,
224
and not in the sex-specific analyses, showed a large variance in expression and, due to limited power,
225
were not detected as statistically significant DEGs in sex-specific analyses (Fig. 2B ). Tumor-infiltrating 226 immune cells may produce spurious signals in DE analyses, which is evident from the detection of 227 various immunoglobulin genes in tumor vs. tumor-adjacent comparisons ( Supplementary Tables S6-8 ).
228
However, male and female samples did not significantly differ in terms of cellular content
229
( Supplementary Table S2 ), and thus such spurious signals are unlikely to affect male-female comparisons.
230
The observed differences in gene expression are thus likely to reflect actual sex-differences rather than 231 confounding differences in sample characteristics or composition.
232
To put these results in a broader context, we analyzed the male-and female-specific DEGs (tumor vs.
233
tumor-adjacent) for the overrepresentation of functional pathways. We found that the sex-shared and sex-234 specific DEGs were enriched in pathways relevant to oncogenesis and cancer progression (Supplementary
235
Tables 9-11). We identified pathways that were overrepresented in only one of the sexes but not in the 236 other or in the combined analysis of both sexes, indicating that male and female HCC are partially driven 237 by different mechanisms and processes ( Fig. 1E-F ).
238
Differential cis-eQTL effects in male and female HCC 239
To further investigate the mechanisms of sex-difference in HCC etiology, we used eQTL analyses to 240 detect germline genetic effects on tumor gene expression in both the joint and sex-stratified analyses (Fig. 
241
3A). We detected 1,204, 761, and 245 eQTLs in the combined, male-specific, and female-specific 242 analyses, respectively (Supplementary Tables S12-14). As expected, genomic annotations show that most 243 eQTLs are located on non-coding regions ( Fig. 3B , Supplementary Tables S15-S17). Consistent with 244 previous reports, most cis-eQTLs were located near transcription start sites (TSSs), with 63% of all 245 eQTLs across the combined and sex-specific analyses being located within 20kb of TSSs. On average, 246 384 variants were tested per gene. 31% of the unique shared and sex-specific cis-eQTLs in HCC were 247 also identified as eQTLs in the liver data in the GTEx project analysis release V7, indicating shared tissue 248 origin. Out of the total of 1,595 unique associations, 75.7% were shared between the sexes. We detected 249 295 male-specific and 92 female-specific eQTLs. Since these associations were not detected in the 250 unstratified analysis, they are likely not a result of differential power to detect associations due to 251 different sample sizes, but exhibit effect modification by sex. Sex-specific associations exhibited 10 differences in effect size between the sexes (based on ANOVA/Kruskal-Wallis tests, Fig. 4C, 4D) , and 253 the sex-specific effect is diluted in the combined analysis ( Fig. 4C, 4D ). Sex-shared large effect eQTLs 254 were detected in sex-specific and combined analyses (Fig. 4A) , and, due to the larger sample size, sex-255 shared low-effect eQTLs are detected in the combined analysis only (Fig. 4B ).
256
We detected 27 shared eGenes that were associated with independent variants in males and females. This 257 could be due to actual biological differences in gene regulation, or due to technical constraints, in 258 particular, missing genotypes in one sex affecting the permutation scheme to select the top-variant for 259 each target gene. To overcome this and to detect high confidence instances of differential gene regulation 260 between the sexes, we further examined the sex-shared and sex-specific eGenes: we found 24 genes that 261 are under germline regulatory control in only male HCC (Fig. 3C) , including POGLUT1, which is an 262 essential regulator of Notch signaling (Fig. 3D) . No genes were found to be associated with nearby 263 variants in females only, likely due to reduced power to detect associations in females (Supplementary 264 Fig. S2 ). Male-specific eGenes were overrepresented in pathways related to cell cycle, apoptosis, and 265 cancer ( Supplementary Table S18 ). Concordant with previous studies [14, 35] , none of the male-specific 266 eGenes were differentially expressed between male and female HCC, indicating that the male-specific 267 eQTLs are not a result of differences in overall gene expression levels between males and females, but are 268 likely to arise from factors such as differential chromatin accessibility or transcription factor activity. The 269 observation that non of the sex-biased autosomal genes in tumors harbor significant cis-eQTLs 270 ( Supplementary Table S19 ) also suggests that while sex-specific cis-eQTLs may contribute to differences 271 in variance, sex-biased gene expression is likely a result of trans-effects, e.g. sex-chromosomal effects on 272 autosomal gene expression, or, more widely, a result of sex as a biological variable, e.g. hormonal effects.
273
Discussion
274
Distinct molecular etiologies of male and female HCC 275
It is well established that patterns of gene expression vary between the sexes across different tissues.
276
Previous studies have confounded these differences with those which may be driving etiological tumors, their approach was limited as it did not include the examination of non-diseased liver nor tumor-281 adjacent tissues. From the results presented here, we are able to distinguish the differences detected in 282 comparisons of male and female HCC from those reflecting sex-differences in the healthy liver or in 283 tumor-adjacent tissue, as well as to detect genes that are dysregulated in HCC in a sex-shared or sex-284 specific manner.
285
We characterized differences in gene expression between male and female HCC cases. Notably, sex-286 differences in gene expression were the largest in the tumor tissue, with 53 genes (including 32 autosomal 287 genes) being expressed in a sex-biased way. These sex-differences point to distinct mechanisms 288 underlying HCC oncogenesis between the sexes, and may partially underlie the observed sex-biases in 289 HCC occurrence and onset. We detected 34 genes that were expressed in a sex-biased way in HCC 290 tumors, but not in healthy or tumor-adjacent liver tissues. Some of these genes are of particular interest in 291 the context of HCC: Notch-regulating DTX1, found here to be underexpressed in males compared to 292 females, has been identified as a putative tumor suppressor gene in head and neck squamous cell 293 carcinoma [36] . Another female-biased gene detected here, CD24, has a crucial role in T cell homeostasis 294 and autoimmunity [37] . The opposing roles of CD24 expression in cancer and autoimmune diseases raise 295 interesting questions on the role of sex-differences in immunity underlying sex-differences in cancer.
296
Future studies will focus on better understanding the differential regulation of immune functions between 297 the sexes, and how these differences contribute to the observed biases in disease occurrence and etiology.
298
By sex-specific analyses of matched tumor and tumor-adjacent samples, we detected genes that are 299 uniquely dysregulated in male and female HCC. Further examination of these genes revealed sex- 
303
PI3K/AKT, FGFR, EGFR, NGF, GF1R, Rap1, DAP12, and IL-2 signaling pathway enrichment (Fig. 1E, 
304
Supplementary Tables 9-10). As these signaling pathways are notable targets for anti-cancer and anti-305 metastasis therapies [38] [39] [40] [41] [42] [43] [44] , the results presented here have implications for the targeted treatment of 306 male and female HCC.
307
Sex-specific germline genetic effects on tumor gene expression may drive the molecular 308 etiologies of male and female HCC 309
Sex-specific regulatory functions may underlie sex-differences in cancer etiology, progression, and 310 outcome. We detected sex-differences in the germline genetic regulation of tumor gene expression in 311 HCC, including 24 genes that were under germline regulatory control only in male HCC (Fig. 3) .
312
Functional annotations of these male-specific eGenes provide insight into possible regulatory mechanisms 313 contributing to the observed male-bias in HCC and sex-differences in HCC etiology. Protein O-314 glucosyltransferase 1 (POGLUT1) was found to be under germline regulation in male HCC, but not in 315 female HCC or in the joint analysis of both sexes (Fig. 3D) . The eQTL associated with POGLUT1 is 316 located on a promoter region of its target ( Supplementary Table S15 ). POGLUT1 is an enzyme that is 317 responsible for O-linked glycosylation of proteins. Altered glycosylation of proteins has been observed in 318 many cancers [45, 46] , including liver cancer [47, 48] . POGLUT1 is an essential regulator of Notch 319 signaling and is likely involved in cell fate and tissue formation during development. Genes involved in 320 Notch and PI3K/AKT signaling were also found to be expressed in a sex-biased way in HCC tumors and 321 overrepresented among the male-specific DEGs detected in the tumor vs. tumor-adjacent comparison,
322
showing that sex-specific eQTLs and sex-specific dysregulated genes converge in canonical pathways.
323
Notch signaling pathway was also detected as overrepresented (FDR-adj. p-value ≤ 0.01) among the 24 324 male-specific eGenes. PI3K-AKT is known to co-operate with Notch by triggering inflammation and 
336
Conclusions 337
In summary, we discovered differential regulatory functions in HCC tumors between the sexes. This work 338 provides a framework for future studies on sex-biased cancers. Further studies are required to identify and 339 validate sex-specific genetic effects on tumor gene expression and its consequences in HCC and other 373 Table S1 . Categorical clinical characteristics of male and female patients in the TCGA LIHC cohort.
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